Last reviewed · How we verify
NCT05482776
HIFT in People With Parkinson's Disease
NA trial testing High intensity functional training in Neurodegenerative Diseases in 14 participants. Completed in 5 December 2022.
3 November 2022
Quick facts
| Lead sponsor | University of Valencia |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | single |
| Primary purpose | treatment |
| Enrollment | 14 |
| Start date | 15 April 2022 |
| Primary completion | 3 November 2022 |
| Estimated completion | 5 December 2022 |
| Sites | 1 location across Spain |
Drugs / interventions tested
- High intensity functional training
- classic training group
Conditions studied
- Neurodegenerative Diseases — all drugs for Neurodegenerative Diseases →
Sponsor
University of Valencia
Who can join
Adults 45 to 80, any sex, with Neurodegenerative Diseases. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Parkinson's disease (PD) is a progressive and chronic neurodegenerative disease, which presents signs and symptoms both motor (impaired gait, posture, balance, etc.) and cognitive (memory loss, dementia, etc.), all of which cause disability and assuming a high economic cost. Currently, there are already certain authors who have shown how a high-intensity interval training (HIIT) protocol produces improvements in cognitive and physical performance in healthy adults and in people with multiple sclerosis. However, another modality has been created, such as high-intensity functional training (HIFT), which can benefit different populations, both healthy and pathological, due to the multimodal nature of the exercises. These are prescribed knowing the target group and involve the whole body using universal motor recruitment patterns in multiple planes of movement such as squats. The main hypothesis of the study is that high-intensity functional training (HIFT), at a motor and cognitive level, provides a greater benefit than conventional programs of strength, balance and cognition, on the functionality and cognitive capacity of people with Parkinson's disease.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05482776
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Neurodegenerative Diseases
Currently open trials in the same condition.
- NCT07324330 — Slowing Cognitive Decline in Alpha-synucleinopathies by Enhancing Physical Activity · NA · recruiting
- NCT07268079 — Validation of the VIRADIA App for Neurological and Cognitive Diagnostics in Virtual Reality · recruiting
- NCT07514520 — Decision-making, Ethical Consent, and Interactive Dialogue in Ongoing Neurocognitive Decline - DECISION · active not recruiting
- NCT06755840 — Sleep Disordered Breathing and Multimorbidity: The Xiangya SDB Cohort Study · recruiting
- NCT06596746 — Neurodegenerative Diseases Progression Markers (MARKERS-NDD) · recruiting
Other University of Valencia trials
Trials by the same sponsor.
- NCT07509281 — Peri-implant Tissues Changes for Different Abutment Shapes and Heights · NA · not yet recruiting
- NCT07535528 — Implant Placement Depth and Peri-Implant Tissue Outcomes · NA · not yet recruiting
- NCT07471555 — Vascular Access and Intraosseus · NA · enrolling by invitation
- NCT07463066 — Long-Term Effectiveness of Pain Neuroscience Education in Women With Genito-Pelvic Pain/Penetration Disorder. · not yet recruiting
- NCT07419399 — Acute Effects of Radiofrequency Diathermy in Postpartum Women With Diastasis Abdominis · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05482776 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Valencia
- Last refreshed: 28 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05482776.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing